Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy
©2024 The Authors; Published by the American Association for Cancer Research..
Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Adding blockade of the anti-programmed cell death protein (PD)-1 pathway to gemcitabine/cisplatin chemotherapy has recently shown efficacy in biliary tract cancers but with low response rates. Here, we studied the effects of anti-cytotoxic T lymphocyte antigen (CTLA)-4 when combined with anti-PD-1 and gemcitabine/cisplatin in orthotopic murine models of ICC. This combination therapy led to substantial survival benefits and reduction of morbidity in two aggressive ICC models that were resistant to immunotherapy alone. Gemcitabine/cisplatin treatment increased tumor-infiltrating lymphocytes and normalized the ICC vessels and, when combined with dual CTLA-4/PD-1 blockade, increased the number of activated CD8+Cxcr3+IFNγ+ T cells. CD8+ T cells were necessary for the therapeutic benefit because the efficacy was compromised when CD8+ T cells were depleted. Expression of Cxcr3 on CD8+ T cells is necessary and sufficient because CD8+ T cells from Cxcr3+/+ but not Cxcr3-/- mice rescued efficacy in T cell‒deficient mice. Finally, rational scheduling of anti-CTLA-4 "priming" with chemotherapy followed by anti-PD-1 therapy achieved equivalent efficacy with reduced overall drug exposure. These data suggest that this combination approach should be clinically tested to overcome resistance to current therapies in ICC patients.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer immunology research - 12(2024), 4 vom: 02. Apr., Seite 400-412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jiang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 08.04.2024 published: Print UpdateOf: bioRxiv. 2023 Jan 27;:. - PMID 36747853 Citation Status MEDLINE |
|---|
| doi: |
10.1158/2326-6066.CIR-23-0486 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367514850 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367514850 | ||
| 003 | DE-627 | ||
| 005 | 20240408232251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2326-6066.CIR-23-0486 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM367514850 | ||
| 035 | |a (NLM)38260999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Jiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD-1 Therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Jan 27;:. - PMID 36747853 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2024 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Adding blockade of the anti-programmed cell death protein (PD)-1 pathway to gemcitabine/cisplatin chemotherapy has recently shown efficacy in biliary tract cancers but with low response rates. Here, we studied the effects of anti-cytotoxic T lymphocyte antigen (CTLA)-4 when combined with anti-PD-1 and gemcitabine/cisplatin in orthotopic murine models of ICC. This combination therapy led to substantial survival benefits and reduction of morbidity in two aggressive ICC models that were resistant to immunotherapy alone. Gemcitabine/cisplatin treatment increased tumor-infiltrating lymphocytes and normalized the ICC vessels and, when combined with dual CTLA-4/PD-1 blockade, increased the number of activated CD8+Cxcr3+IFNγ+ T cells. CD8+ T cells were necessary for the therapeutic benefit because the efficacy was compromised when CD8+ T cells were depleted. Expression of Cxcr3 on CD8+ T cells is necessary and sufficient because CD8+ T cells from Cxcr3+/+ but not Cxcr3-/- mice rescued efficacy in T cell‒deficient mice. Finally, rational scheduling of anti-CTLA-4 "priming" with chemotherapy followed by anti-PD-1 therapy achieved equivalent efficacy with reduced overall drug exposure. These data suggest that this combination approach should be clinically tested to overcome resistance to current therapies in ICC patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 700 | 1 | |a Amoozgar, Zohreh |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Shuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zelong |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Sarah M |e verfasserin |4 aut | |
| 700 | 1 | |a Matsui, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Alexei |e verfasserin |4 aut | |
| 700 | 1 | |a Pu, Zhangya |e verfasserin |4 aut | |
| 700 | 1 | |a Halvorsen, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Pin-Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Datta, Meenal |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Lingling |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Zhiping |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Staiculescu, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Koetsu |e verfasserin |4 aut | |
| 700 | 1 | |a Munn, Lance L |e verfasserin |4 aut | |
| 700 | 1 | |a Fukumura, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Peigen |e verfasserin |4 aut | |
| 700 | 1 | |a Sassi, Slim |e verfasserin |4 aut | |
| 700 | 1 | |a Bardeesy, Nabeel |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Won Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Rakesh K |e verfasserin |4 aut | |
| 700 | 1 | |a Duda, Dan G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology research |d 2013 |g 12(2024), 4 vom: 02. Apr., Seite 400-412 |w (DE-627)NLM234031611 |x 2326-6074 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:400-412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2326-6066.CIR-23-0486 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 4 |b 02 |c 04 |h 400-412 | ||